

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of Gordon BRUTON et al.

International Application No.: PCT/EP2004/011619

International Filing Date: October 14, 2004

**For:** 1-Benzoyl Substituted Diazepine Derivatives as Selective  
Histamine H3 Receptor Agonists

**Commissioner for Patents**  
**P.O. Box 1450**  
**Alexandria, VA 22313-1450**

## INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

☒ Copies of the references are enclosed

☐ Copies of the references were submitted in parent application Serial No. \_\_\_\_\_.  
(37 CFR 1.98(d))

☒ A copy of the International Search Report which issued on International Application No. PCT/EP2004/011619 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

B. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:


- (1) a final action under § 1.113 or
- (2) a notice of allowance under § 1.311,

whichever occurs first.

Express Mail Label No.: EV332130977US

Date of Mailing: April 18, 2006

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to "Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on the date shown above.


  
Patty Wilson

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).
- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]
- ☐ Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- ☐ The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.
- [X] Please charge any required fees to Deposit Account No.07-1392.
- ☐ A duplicate copy of this paper is attached.

Respectfully Submitted,



Kimberly H. Parker  
Attorney of Record  
Registration No. 47,843

Date: April 18, 2006  
Customer No. 23347  
GlaxoSmithKline  
Corporate Intellectual Property  
5 Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Telephone: (919) 483-8406  
Facsimile: (919) 483-7988

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				INT'L FILING NO.		PCT/EP2004/011619	
				INT'L FILING DATE		October 14, 2004	
				APPLICANT		Bruton et al.	
				GROUP			
				EXAMINER			
				ATTORNEY DOCKET NO.		PB60543USw	
U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes   No
	1.	WO02/12190	2/14/2002	PCT			
	2.	WO03/024917	3/27/2003	PCT			
	3.	WO03/066604	8/14/2003	PCT			
	4.	WO04/035556	11/29/04	PCT			
	5.	WO03/00480	1/3/2003	PCT			
	6.	WO02/08221	1/31/2002	PCT			
	7.	WO98/37077	8/27/1998	PCT			
	8.	WO99/42107	1/26/1999	PCT			
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
	9.	COTTET and SCHLOSSER, Trifluoromethyl-Substituted Pyridines Through Displacement of Iodine by in situ Generated (Trifluoromethyl)copper, Eur. J. Org. Chem. 2002:327-330 (2002).					
	10.	FUKUI et al., Molecular Cloning of the Human Histamine H1 Receptor Gene, Biochem and Biophys Res. Commun. 201(2):894-901 (1994).					
	11.	GIOVANNINI et al., Effects of histamine H <sub>3</sub> receptor agonists and antagonists on cognitive performance and scopolamine-induced amnesia, Behavioural Brain Research 104:147-155 (1999).					
	12.	LEURS et al., Therapeutic potential of histamine H <sub>3</sub> receptor agonists and antagonists, TiPS 19:177-183 (May 1998).					
	13.	LOVENBERG et al., Cloning and Functional Expression of the Human Histamine H <sub>3</sub> Receptor, Molecular Pharmacology 55:1101-1107 (1999).					
	14.	ONODERA and WATANABE, Histamine H <sub>3</sub> Antagonists as Potential Therapeutics in the CNS, The Histamine H <sub>3</sub> Receptor A Target for New Drugs, ed. Leurs and Timmerman 255-267 (1998).					
	15.	SCHLICKER et al., Modulation of neurotransmitter release <i>via</i> histamine H <sub>3</sub> heteroreceptors, Fundam. Clin. Pharmacol. 8:128-137 (1994).					
	16.	YOUNG and DEVITA, Novel Synthesis of Oxadiazoles <i>via</i> Palladium Catalysis, Tetrahedron Lett 39:3931-3934 (1998).					
	17.	SMIT et al., Regulation of the human histamine H <sub>1</sub> receptor stably expressed in Chinese hamster ovary cells, British Journal Pharmacology 117(6):1071 (1996).					
EXAMINER					DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							